ArticleBMC medical genomics2026
Single-cell RNA sequencing of adenoid cystic carcinoma of the breast reveals cellular heterogeneity and tumor microenvironment features.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAdenoid cystic carcinoma of the breast (ACCB) is a rare malignant tumor with distinct pathological features and a relatively favorable prognosis compared to other breast cancer subtypes, yet its molecular mechanisms remain poorly understood due to challenges in sample acquisition and targeted research.
methodsIn this study, we employed single-cell RNA sequencing (scRNA-seq) to systematically characterize the cellular heterogeneity and tumor microenvironment in ACCB. We obtained scRNAseq data from a single patient with ACCB and integrated it with publicly available datasets from head and neck adenoid cystic carcinoma (HNACC) and triple-negative breast cancer (TNBC). Through high-resolution gene expression profiling, cell clustering, differential expression analysis, and cell-cell communication analysis, we aimed to identify key malignant subpopulations and regulatory networks in ACCB.
resultsUnsupervised clustering revealed seven major cell types in the analyzed ACCB sample, including epithelial cells, fibroblasts, and immune cells. In-depth analysis of epithelial cells identified H19 + myoepithelial cells (H19 + myoEpC) as the dominant malignant subpopulation, enriched in ACCB compared to other cancers and characterized by high expression of oncogenic pathways and ligands such as LAMB1 and WNT6. Tumor-associated fibroblasts exhibited significant heterogeneity, with cancer-associated fibroblasts (CAFs) expressing EMT-related genes and interacting closely with H19 + myoEpC. The tumor microenvironment was immunosuppressive, with reduced infiltration of CD4 + and CD8 + T cells and B cells, and lacked classical Treg/Tex populations. Comprehensive cell-cell communication analysis showed that H19 + myoEpC orchestrated a signaling network with CAFs, immune cells, and endothelial cells, driving tumor progression and immune evasion.
conclusionsOur study provides the single-cell resolution map of ACCB from a representative case, highlighting the unique role of H19 + myoEpC in tumor progression and immune suppression. These findings offer new insights into the molecular classification of ACCB and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.